

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE


In re patent application of

Thomas M. BEHR et al.

Serial No. 09/200,791

Filed: November 30, 1998

For: METHODS OF REDUCED RENAL UPTAKE OF PROTEIN CONJUGATES



Attorney Docket No. 018734/0161

Group Art Unit: 1642

Examiner: J. Burke

AF  
914 1642  
RECEIVED  
OCT 23 2000  
10/24/00  
TECH CENTER 16042902  
1642  
Gray

Reply under 37 C.F.R. § 1.116

Assistant Commissioner for Patents  
Washington, D.C. 20231

Sir:

In response to the Office Action mailed July 18, 2000, please amend the above-identified application as follows:

In the Specification:

In the first sentence of the specification noting the priority of the instant application, please change "U.S. Patent No. 5,843,849" to -- ~~U.S.~~ Patent No. 5,843,894 --.

On page 5, in the section titled "Brief Description of the Drawings":

please delete "Figure 2 shows the dose-effect relationship between L-lysine hydrochloride, administered intraperitoneally in hourly intervals, and the kidney uptake of <sup>99m</sup>Tc-labeled Fab' fragments of the anti-CEA MAb NP-4 in BALB/c mice, after 4h (upper graph) or 24h (lower graph) post-injection.", and insert therefore:

-- Figure 2A shows the dose-effect relationship between L-lysine hydrochloride, administered intraperitoneally in hourly intervals, and the kidney uptake of <sup>99m</sup>Tc-labeled Fab' fragments of the anti-CEA MAb NP-4 in BALB/c mice, after 4 hours post-injection.